Trial
NCT05254990
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Dompé Farmaceutici S.p.A
Collaborators
—
Condition
Infectious Pneumonia
Intervention
Reparixin
Why stopped
The study was stopped due to futility as per protocol
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-24